Company Overview

ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology therapies designed to help the immune system recognize and destroy cancer cells. The company primarily operates in the biotechnology and oncology therapeutics industries, with a strategic emphasis on therapies targeting the CD47 pathway, a signaling mechanism used by cancer cells to evade immune detection. ALX Oncology’s lead product candidate is evorpacept (ALX148), an engineered fusion protein intended to block CD47 while minimizing hematologic toxicities associated with earlier CD47-targeting therapies. The company’s development programs are concentrated in solid tumors and hematologic malignancies, often in combination with established anti-cancer therapies such as monoclonal antibodies and checkpoint inhibitors.

The company was founded in 2015 and is headquartered in South San Francisco, California. ALX Oncology evolved from scientific research into CD47 biology and macrophage checkpoint inhibition, positioning itself within a competitive field of next-generation immunotherapies. Its strategic differentiation has centered on the design of evorpacept’s inactive Fc domain, which is intended to reduce damage to healthy blood cells while preserving anti-tumor activity. Revenue generation has historically been limited, as the company remains in the clinical development stage and has not reported commercial product sales based on publicly available filings.

Business Operations

ALX Oncology’s operations are primarily organized around its oncology research and development activities rather than diversified commercial segments. The company’s core business consists of advancing clinical-stage therapeutic candidates through preclinical research, clinical trials, regulatory engagement, and strategic collaborations. Its principal asset, evorpacept, has been evaluated in combination regimens involving therapies such as trastuzumab, pembrolizumab, and rituximab across multiple cancer indications. The company generates operating capital primarily through equity financing, public market offerings, and collaboration-related arrangements rather than recurring commercial revenue.

The company’s operations are centered in the United States, though clinical studies have included sites in multiple international jurisdictions. ALX Oncology controls intellectual property related to its CD47 blockade platform and associated therapeutic engineering technologies. Public disclosures identify collaborations and clinical relationships with large pharmaceutical companies involved in combination therapy development, including partnerships connected to HER2-targeted and checkpoint inhibitor regimens. The company has also relied on contract research organizations and manufacturing partners to support clinical development and biologics production.

Strategic Position & Investments

ALX Oncology’s strategic direction has focused on advancing evorpacept through mid- and late-stage clinical development while identifying tumor settings where macrophage-mediated immune activation may improve outcomes when combined with established therapies. The company has concentrated investment in indications such as gastric cancer, head and neck cancer, breast cancer, and hematologic malignancies. Its strategy reflects broader industry interest in innate immune system modulation as a complement to T-cell-focused immunotherapies.

The company has invested heavily in clinical trial expansion and translational oncology research to support combination-based treatment approaches. Public filings and investor materials indicate continued prioritization of oncology programs with biomarker-driven or antibody-combination potential. ALX Oncology does not publicly report a broad portfolio of subsidiaries or diversified operating businesses, as its activities remain primarily focused on advancing its lead therapeutic platform. The company’s strategic positioning depends substantially on clinical trial outcomes, regulatory progress, and the competitive evolution of the CD47 therapeutic landscape.

Geographic Footprint

ALX Oncology is headquartered in South San Francisco, California, a major biotechnology hub within the United States. The company’s principal corporate and research activities are concentrated domestically, including executive management, clinical oversight, and corporate administration. Its operations are supported by collaborations with external manufacturers, research organizations, and clinical trial sites.

Although ALX Oncology does not maintain the broad global commercial footprint of large pharmaceutical companies, its clinical programs have involved investigators and trial locations across North America, Europe, and parts of the Asia-Pacific region. The company’s international presence is primarily tied to multinational clinical development activities and regulatory engagement associated with oncology trials.

Leadership & Governance

ALX Oncology was co-founded by researchers and biotechnology executives involved in the development of macrophage checkpoint therapies. The company is led by an executive team with backgrounds in oncology drug development, biologics commercialization, and biotechnology finance. Public communications and filings emphasize a strategy centered on disciplined clinical execution, differentiated immunotherapy design, and combination-based oncology development.

Key executives identified in recent public filings include:

• Jason Lettmann – Chief Executive Officer
• Sophia Randolph, M.D., Ph.D. – Chief Medical Officer
• Laurel A. Shields – Chief Financial Officer
• Jaume Pons, Ph.D. – Founder and former executive leader associated with the company’s scientific development
• Peter S. Garcia – Chief Legal Officer and Corporate Secretary

The company’s governance framework includes a board of directors with experience across biotechnology, pharmaceutical development, finance, and public company operations. Strategic leadership has consistently emphasized advancing clinically differentiated immuno-oncology therapies while maintaining financial discipline during the development stage.